Genmab | Pasivo Circulante



Current Liabilities Cambio Fecha
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Almirall EUR 274.01M 14.41M 2024-06
Amarin USD 201.55M 28.99M 2024-09
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Bayer EUR 28.95B 3.9B 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Demant DKK 6.1B 1.4B 2024-12
Exelixis USD 403.77M 9.42M 2025-01
Fresenius Medical Care EUR 5.66B 228.94M 2024-12
Galapagos EUR 335.08M 16.15M 2024-12
Genmab DKK 5.31B 723M 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
GN Store Nord DKK 2.21B 11.18B 2024-12
GRIFOLS EUR 2.16B 199.43M 2024-12
Hikma Pharmaceutical USD 1.38B 41M 2024-06
Insmed USD 297.53M 38.34M 2024-12
Lonza CHF 3.58B 970M 2024-12
Merck EUR 10.46B 532M 2024-09
Novartis USD 28.69B 560M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 30.03B 5.82B 2024-06
UCB EUR 3.53B 731M 2024-12



Genmab Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.